Therapeutic Targeting of Amyloid Precursor Protein and its Processing Enzymes for Breast Cancer Treatment

Syed Mohd Danish Rizvi1, Talib Hussain1, Gehad M Subaiea1

  • 1Department of Pharmacology and toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia.

Insights

Amyloid precursor protein (APP) and its processing enzymes show promise as novel targets for breast cancer treatment. Targeting these proteins may offer new therapeutic strategies for combating breast cancer and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer incidence is rising globally, necessitating novel therapeutic targets.
  • Amyloid precursor protein (APP) and its processing enzymes are implicated in cancer cell proliferation and metastasis.
  • While studied in Alzheimer's, APP's role extends to non-neuronal cells, including breast cancer cells.

Purpose of the Study:

  • To investigate amyloid precursor protein (APP) and its processing enzymes as potential therapeutic targets for breast cancer.
  • To review the linkages between APP, secretases (α-secretase, β-secretase, γ-secretase), and breast cancer.
  • To summarize current treatment strategies targeting APP and its processing enzymes.

Main Methods:

  • Comprehensive literature review of studies on APP and its processing enzymes in breast cancer.
  • Analysis of the role of APP and secretases in cancer cell proliferation, growth, adherence, and movement.
  • Examination of signaling pathways (Akt phosphorylation, Notch signaling) linking APP to breast cancer.

Main Results:

  • Over-synthesis of APP and its processing enzymes (γ-secretase, α-secretase) are key features in breast cancer.
  • APP and secretases are linked to breast cancer progression via Akt phosphorylation and Notch signaling.
  • Targeting APP, γ-secretase, or α-secretase presents a viable strategy for breast cancer and metastasis treatment.

Conclusions:

  • APP and its processing enzymes represent promising targets for novel breast cancer therapies.
  • Targeting these proteins could lead to effective treatments for both primary tumors and metastatic disease.
  • Ongoing clinical trials are exploring γ-secretase inhibitors for breast cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30